Placebo-controlled, double-blind clinical trial of alprenolol in African hypertensive patients.
A placebo-controlled, double-blind clinical trial of alprenolol was carried out in 20 hypertensive Africans. The active drug and placebo were each administered for 8 weeks using a crossover design. Alprenolol was given in the form of a slow-release tablet preparation at a dosage of 200 mg twice daily. Four patients were withdrawn from the study either because of side-effects (2 patients) or non-compliance (2 patients). The mean reduction in blood pressure obtained in the 16 patients who completed the trial was less than that usually reported in Caucasians.
D000328:Adult; D000526:Alprenolol / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009549:Nigeria; D011674:Pulse / Q000187:drug effects; D013997:Time Factors
D000526:Alprenolol